Tags

Type your tag names separated by a space and hit enter

Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination.
Ophthalmology 2003; 110(7):1357-60O

Abstract

PURPOSE

To evaluate the efficacy and safety of commercially available latanoprost 0.005% given every evening versus timolol 0.5% and dorzolamide 2% fixed combination (TDFC) given twice daily to white Greeks with primary open-angle glaucoma and ocular hypertensive patients.

DESIGN

A single-masked, two-center, crossover comparison with two 6-week treatment periods occurring after at least a 3-week medicine-free period. Diurnal curve intraocular pressures were taken at 2:00 AM, 6:00 AM, 10:00 AM, 2:00 PM, 6:00 PM, and 10:00 PM.

PARTICIPANTS

Thirty-four subjects with primary open-angle glaucoma or ocular hypertension were enrolled.

INTERVENTIONS

Latanoprost 0.005% given every evening and TDFC twice daily.

MAIN OUTCOME MEASURES

The primary efficacy variable was diurnal intraocular pressure.

RESULTS

Thirty-three patients completed the study. On the last day of treatment, the mean diurnal intraocular pressure for latanoprost was 15.9 +/- 2.3 mmHg and for TDFC was 15.3 +/- 2.0 mmHg (P = 0.05). Individual time points for intraocular pressure were not statistically different between groups except at the 10:00 PM time point, when the mean for TDFC was 14.6 +/- 2.7 mmHg and for latanoprost was 16.6 +/- 3.1 mmHg (P < 0.006). Eighteen patients overall preferred latanoprost versus 2 patients for the fixed combination, generally because of the greater convenience of once daily dosing. Adverse events were not significantly different between groups except that a bitter taste was found more frequently with TDFC (n = 9) than with latanoprost (n = 0; P = 0.009). Despite screening to exclude intolerance to beta-blockers, a single patient had to discontinue the TDFC because of new-onset asthma.

CONCLUSIONS

This study indicates that the 24-hour diurnal intraocular pressure is lowered more, by a small but statistically significant amount, with TDFC compared with latanoprost in primary open-angle glaucoma and ocular hypertensive patients.

Authors+Show Affiliations

University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

12867391

Citation

Konstas, Anastasios G P., et al. "Twenty-four-hour Diurnal Curve Comparison of Commercially Available Latanoprost 0.005% Versus the Timolol and Dorzolamide Fixed Combination." Ophthalmology, vol. 110, no. 7, 2003, pp. 1357-60.
Konstas AG, Papapanos P, Tersis I, et al. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology. 2003;110(7):1357-60.
Konstas, A. G., Papapanos, P., Tersis, I., Houliara, D., & Stewart, W. C. (2003). Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology, 110(7), pp. 1357-60.
Konstas AG, et al. Twenty-four-hour Diurnal Curve Comparison of Commercially Available Latanoprost 0.005% Versus the Timolol and Dorzolamide Fixed Combination. Ophthalmology. 2003;110(7):1357-60. PubMed PMID: 12867391.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. AU - Konstas,Anastasios G P, AU - Papapanos,Panayiotis, AU - Tersis,Ioannis, AU - Houliara,Dimitra, AU - Stewart,William C, PY - 2003/7/18/pubmed PY - 2003/7/29/medline PY - 2003/7/18/entrez SP - 1357 EP - 60 JF - Ophthalmology JO - Ophthalmology VL - 110 IS - 7 N2 - PURPOSE: To evaluate the efficacy and safety of commercially available latanoprost 0.005% given every evening versus timolol 0.5% and dorzolamide 2% fixed combination (TDFC) given twice daily to white Greeks with primary open-angle glaucoma and ocular hypertensive patients. DESIGN: A single-masked, two-center, crossover comparison with two 6-week treatment periods occurring after at least a 3-week medicine-free period. Diurnal curve intraocular pressures were taken at 2:00 AM, 6:00 AM, 10:00 AM, 2:00 PM, 6:00 PM, and 10:00 PM. PARTICIPANTS: Thirty-four subjects with primary open-angle glaucoma or ocular hypertension were enrolled. INTERVENTIONS: Latanoprost 0.005% given every evening and TDFC twice daily. MAIN OUTCOME MEASURES: The primary efficacy variable was diurnal intraocular pressure. RESULTS: Thirty-three patients completed the study. On the last day of treatment, the mean diurnal intraocular pressure for latanoprost was 15.9 +/- 2.3 mmHg and for TDFC was 15.3 +/- 2.0 mmHg (P = 0.05). Individual time points for intraocular pressure were not statistically different between groups except at the 10:00 PM time point, when the mean for TDFC was 14.6 +/- 2.7 mmHg and for latanoprost was 16.6 +/- 3.1 mmHg (P < 0.006). Eighteen patients overall preferred latanoprost versus 2 patients for the fixed combination, generally because of the greater convenience of once daily dosing. Adverse events were not significantly different between groups except that a bitter taste was found more frequently with TDFC (n = 9) than with latanoprost (n = 0; P = 0.009). Despite screening to exclude intolerance to beta-blockers, a single patient had to discontinue the TDFC because of new-onset asthma. CONCLUSIONS: This study indicates that the 24-hour diurnal intraocular pressure is lowered more, by a small but statistically significant amount, with TDFC compared with latanoprost in primary open-angle glaucoma and ocular hypertensive patients. SN - 0161-6420 UR - https://www.unboundmedicine.com/medline/citation/12867391/Twenty_four_hour_diurnal_curve_comparison_of_commercially_available_latanoprost_0_005_versus_the_timolol_and_dorzolamide_fixed_combination_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(03)00404-4 DB - PRIME DP - Unbound Medicine ER -